DEFENDO Long-Term Follow-up Study
Brief description of study
The purpose of this study is to evaluate the long-term safety and efficacy of Oxervate 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 Neurotrophic Keratitis patients who enrolled in the DEFENDO study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
09 Mar 2024.
Study ID: 852042
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
